We are live on
!
Find out more
CC
Callan Capital Portfolio holdings
AUM
$1.35B
Turnover
17.35%
1-Year Est. Return
8.35%
This Fund
S&P 500
This Quarter
Est. Return
-0.8%
1 Year Est. Return
+8.35%
3 Year Est. Return
+20.11%
5 Year Est. Return
+98.58%
10 Year Est. Return
+95.87%
AUM
$245M
AUM Growth
+$6.42M
(+2.7%)
Cap. Flow
+$10.6M
Cap. Flow
% of AUM
4.35%
Top 10 Holdings %
Top 10 Hldgs %
74.43%
Holding
71
New
8
Increased
23
Reduced
20
Closed
3
Avg Time Held
1.8
years
Top 10 Avg Time Held
1.1
years
Top 20 Avg Time Held
1.4
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard Short-Term Corporate Bond ETF
VCSH
|
+$3.19M |
| 2 |
Vanguard FTSE All-World ex-US ETF
VEU
|
+$2.07M |
| 3 |
Vanguard Total Bond Market
BND
|
+$2.06M |
| 4 |
Goldman Sachs ActiveBeta US Large Cap Equity ETF
GSLC
|
+$1.63M |
| 5 |
Schwab Fundamental US Broad Market Index ETF
FNDB
|
+$1.33M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Schwab US Broad Market ETF
SCHB
|
+$1.46M |
| 2 |
Schwab International Equity ETF
SCHF
|
+$742K |
| 3 |
Neurocrine Biosciences
NBIX
|
+$322K |
| 4 |
Xtrackers MSCI EAFE Hedged Equity ETF
DBEF
|
+$279K |
| 5 |
ResMed
RMD
|
+$263K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 86.18% |
| 2 | Healthcare | 12.42% |
| 3 | Real Estate | 0.47% |
| 4 | Financials | 0.35% |
| 5 | Materials | 0.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
51
Tesla
TSLA
$1.43T
| $278K | 0.11% |
19,650
-3,750
| -16% | -$56.8K |
2014 Q2
8 quarters
|
|
52
DELISTED
CATALENT, INC.
CTLT
| $269K | 0.11% |
+11,700
| New | +$309K |
2016 Q2
0 quarters
|
|
53
WisdomTree US LargeCap Dividend Fund
DLN
$6.31B
| $260K | 0.11% |
6,872
-648
| -9% | -$24K |
2013 Q2
12 quarters
|
|
54
iShares MSCI Pacific ex Japan ETF
EPP
$2.21B
| $248K | 0.1% |
6,330
+998
| +19% | +$39.1K |
2013 Q2
12 quarters
|
|
55
Illumina
ILMN
$40.5B
| $242K | 0.1% |
1,772
+41
| +2% | +$5.82K |
2014 Q1
9 quarters
|
|
56
Vanguard FTSE Emerging Markets ETF
VWO
$124B
| $241K | 0.1% |
6,832
-5,065
| -43% | -$173K |
2013 Q2
12 quarters
|
|
57
iShares Core S&P 500 ETF
IVV
$889B
| $215K | 0.09% |
1,020
| – | – |
2015 Q4
2 quarters
|
|
58
DELISTED
Pacific Premier Bancorp
PPBI
| $213K | 0.09% |
+8,862
| New | +$206K |
2016 Q2
0 quarters
|
|
59
DELISTED
Assertio
ASRT
| $210K | 0.09% |
178
| – | – |
2014 Q2
8 quarters
|
|
|
WMAR
60
DELISTED
West Marine Inc
WMAR
| $169K | 0.07% |
+20,200
| New | +$186K |
2016 Q2
0 quarters
|
|
|
SQNM
61
DELISTED
SEQUENOM INC NEW
SQNM
| $162K | 0.07% |
176,777
| – | – |
2013 Q3
11 quarters
|
|
|
HNGR
62
DELISTED
Hanger Inc.
HNGR
| $155K | 0.06% |
20,836
| – | – |
2015 Q3
3 quarters
|
|
63
Bank of America
BAC
$362B
| $133K | 0.05% |
10,009
| – | – |
2015 Q4
2 quarters
|
|
64
DELISTED
Cidara Therapeutics
CDTX
| $122K | 0.05% |
+593
| New | +$144K |
2016 Q2
0 quarters
|
|
|
APTO
65
DELISTED
Aptose Biosciences, Inc.
APTO
| $29K | 0.01% |
27
| – | – |
2015 Q4
2 quarters
|
|
66
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
| – | – |
0
| – | – |
2014 Q2
8 quarters
|
|
|
BIOC
67
DELISTED
Biocept, Inc.
BIOC
| $25K | 0.01% |
1
| – | – |
2015 Q1
5 quarters
|
|
|
ARNA
68
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $21K | 0.01% |
+1,200
| New | +$21.5K |
2016 Q2
0 quarters
|
|
|
69
Xtrackers MSCI EAFE Hedged Equity ETF
DBEF
$9.26B
| – | – |
-10,918
| Closed | -$279K | – |
|
70
iShares Russell 1000 ETF
IWB
$49.2B
| – | – |
-2,157
| Closed | -$246K | – |
|
71
DELISTED
Regulus Therapeutics
RGLS
| – | – |
-238
| Closed | -$198K | – |
|
Similar funds
PRO
MBA
SIA
AP
MW
SBIA
LC
TW
Callan Capital's Q2 2016 Portfolio in Review
As of Q2 2016, Callan Capital held 71 positions worth $245M, up 2.7% from $239M the previous quarter. Its ten largest holdings account for 74% of the portfolio.
Callan Capital deployed $10.6M of net new capital in Q2 2016, opening 8 new positions and adding to 23 existing holdings. Its largest new stake was Schwab Fundamental US Broad Market Index ETF: 134,202 shares worth $1.34M.
By sector, the portfolio is most concentrated in Miscellaneous at 86% of assets, up from 83% a quarter earlier, followed by Healthcare and Real Estate.
On the sell side, the largest reduction was Schwab US Broad Market ETF, an estimated $1.46M trimmed.
- Callan Capital's largest Q2 2016 buy was Schwab Fundamental US Broad Market Index ETF: 134,202 shares worth $1.34M.
- Callan Capital added most to Vanguard Short-Term Corporate Bond ETF in Q2 2016, an estimated $3.19M increase.
- Callan Capital's biggest Q2 2016 reduction was Schwab US Broad Market ETF, cutting an estimated $1.46M.
- Callan Capital fully exited Xtrackers MSCI EAFE Hedged Equity ETF in Q2 2016, selling an estimated $279K.
- Callan Capital's ten largest holdings make up 74% of its $245M portfolio in Q2 2016.
- Callan Capital opened 8 new positions and closed 3 in Q2 2016.
- Callan Capital's portfolio value rose 2.7% quarter-over-quarter to $245M.
Based on Callan Capital's 13F filing for Q2 2016, filed 12 Aug 2016.